Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Atrial fibrillation (AF) is a very common arrhythmia causing many symptoms resulting in numerous hospitalizations. Catheter ablation is a technique that has evolved significantly to improve symptomatic recurrences, but does not offer a 100% cure rate. We hypothesize that the use of aggressive BP lowering will reduce the rate of recurrent AF after catheter ablation for AF. We plan a randomized clinical trial of aggressive BP lowering versus standard BP control to investigate this.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nova Scotia Health Authority
• Collaborator: Nova Scotia Health Research Foundation
• Treatments: Amlodipine; Atenolol; Hydrochlorothiazide; Quinapril; Terazosin

Criteria

Inclusion Criteria:

• Documented systolic blood pressure greater than or equal to 130 mmHg

• Undergoing planned catheter ablation for persistent AF (lasting > 7 days and < 365 days or requiring electrical or chemical cardioversion) OR High burden paroxysmal AF > 6 months (greater than or equal to 3 symptomatic episdes in past 6 months and refractory or inteolerant to at least 1 class 1 or 3 antiarrhythmic)

Exclusion Criteria:

• Permanent atrial fibrillation

• Contraindication to Accupril or any other ACE-I

• Women of child-bearing potential

• Life expectancy less than 1 year

• Less than 18 years of age

• Unable to give informed consent

• Known moderate to several renal dysfunction (eGFR < 30 ml/min/1.73m2)

• Prior AF catheter ablation